Avedro, Inc.
Avedro Inc. Part of Glaukos Corporation
- UEI
- XVMEKBSUMGZ7
- CAGE
- 59N76
- Primary NAICS
- 339112 Surgical and Medical Instrument Manufacturing
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Glaukos Corporation
Parent
M77LMBPAZLL9
- Avedro, Inc. XVMEKBSUMGZ7
-
Glaukos Corporation
Parent
M77LMBPAZLL9
- SAM.gov registration date
- Website
- glaukos.com
- Founded
- 1998
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Equipment & Supplies
- Eyewear
- SIC code
- 59 Miscellaneous Retail
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Travoprost 75MCG | Veterans Integrated Service Network 12 | $169,105 | |
| Idose TR 75 MGC implant | Veterans Integrated Service Network 5 | $10,655 | |
| Pros implant | Veterans Integrated Service Network 19 | $21,311 | |
| Pros implant | Veterans Integrated Service Network 19 | $21,311 | |
| Pros implant | Veterans Integrated Service Network 19 | $21,311 |
About Avedro, Inc.
Avedro, Inc., a subsidiary of Glaukos Corporation, manufactures specialized ophthalmic medical devices and pharmaceutical implants sold to the Department of Veterans Affairs and the Defense Health Agency as a full-and-open federal prime contractor without set-aside participation. The company competes on a firm-fixed-price basis across purchase orders, delivery orders, and blanket purchase agreements and holds no SBA designations.
Avedro operates as a 100% prime contractor (24 awards across the source period, zero sub awards) supplying advanced eye-care implants and ophthalmic pharmaceuticals to federal healthcare systems. The product portfolio centers on IDOSE TRAVOPROST 75MCG implants, IDOSE TR ophthalmic implants, and PROS implants — specialized devices for glaucoma and ocular hypertension treatment. Representative prime work includes a $213,105.60 delivery order from Veterans Integrated Service Network 15 for IDOSE TRAVOPROST 75MCG implants (July 2024), a $95,897.52 delivery order from VISN 12 for IDOSE TR 75 CMG implants (June 2024), and a $21,310.56 purchase order from VISN 19 for PROS implants (April 2025). Performance is based at Avedro's Waltham, Massachusetts facility.
Customer concentration is heavily weighted toward military health services. The Defense Health Agency dominates by combined potential value at $8.2 million across four awards (86% of total potential value), followed by three VA regional networks — VISN 15 ($341 thousand), VISN 12 ($290 thousand), and VISN 19 ($85 thousand) — and the Army Medical Command ($325 thousand). Top-five customers account for 97% of combined potential value. The company serves nine distinct customer agencies in total, reflecting broad federal healthcare system exposure but concentrated dollar value in defense health systems.
Avedro holds two active Federal Supply Schedule vehicles under the Pharmaceuticals and Drugs (FSS-61-IB) schedule: a single-award Blanket Purchase Agreement (BPA) with a $106,552.80 ceiling running through January 31, 2030, and a prior Federal Supply Schedule contract with a $584,000.00 ceiling. Seven task orders have been placed against the Pharmaceuticals and Drugs parent vehicle, generating $638 thousand in combined potential value. This indefinite delivery framework enables streamlined ordering across multiple VA regional networks.
Award activity has been modest and episodic. The company received two awards in 2018, one in 2022, four in 2024, five in 2025, and one in 2026. Combined potential value across all 24 awards is $9.5 million, of which $1.4 million has been obligated (15% execution rate). One award with $169 thousand in potential value faces ultimate completion in the next twenty-four months, indicating limited near-term recompete exposure. The company's category concentration clusters in Surgical and Medical Instrument Manufacturing (NAICS 339112, 14 awards) and Pharmaceutical Preparation Manufacturing (NAICS 325412, 7 awards), with secondary coding under Ophthalmic Goods Manufacturing (NAICS 339115, 1 award), reflecting its parent Glaukos Corporation's core market position in eye-care innovation and Avedro's role as the operating subsidiary delivering ophthalmic medical technologies to the federal healthcare market.
Contract vehicles
Quick answers
What is Avedro, Inc.'s UEI?
Avedro, Inc.'s Unique Entity ID (UEI) in SAM.gov is XVMEKBSUMGZ7.
What is Avedro, Inc.'s CAGE code?
Avedro, Inc.'s CAGE code is 59N76.
What is Avedro, Inc.'s primary NAICS code?
Avedro, Inc.'s primary NAICS code is 339112 (Surgical and Medical Instrument Manufacturing).
Is Avedro, Inc. registered in SAM.gov?
Avedro, Inc.'s SAM.gov registration expired on June 17, 2026.
Who is Avedro, Inc.'s parent company?
Avedro, Inc. is part of Glaukos Corporation.
Which contract vehicles does Avedro, Inc. hold?
Avedro, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Avedro, Inc.'s most recent federal award?
Avedro, Inc.'s most recent federal contract award is Travoprost 75MCG (36C25226N0252), from Veterans Integrated Service Network 12, on February 1, 2026.
On GovTribe
See Avedro, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors